NCT04072861

A Study of RBT-9 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease

A Phase 1b Dose-escalating Study With RBT-9 in Healthy Volunteers and Volunteers With Chronic Kidney Disease Stage 3/4

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Renibus Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 1b, single-center, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effect of RBT-9 in healthy volunteers and in subjects with Stage 3/4 CKD.

Conditions

• Healthy Volunteers
• Chronic Kidney Disease

Interventions

Type	Name	Description
DRUG	RBT-9	intravenous administration

Timeline

• Start date: 2019-03-31
• Primary completion: 2020-07-31
• Completion: 2020-10-31
• First posted: 2019-08-28
• Last updated: 2025-01-06
• Results posted: 2025-01-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study